Cargando…

PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers

BACKGROUND: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer’s disease (AD). OBJECTIVE: We sought to characterize the relationship between Aβ and tau ligands as well as with other measures of pathology. METHODS: We conducted a multi-center ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koychev, Ivan, Gunn, Roger N., Firouzian, Azadeh, Lawson, Jennifer, Zamboni, Giovanna, Ridha, Basil, Sahakian, Barbara J., Rowe, James B., Thomas, Alan, Rochester, Lynn, Ffytche, Dominic, Howard, Robert, Zetterberg, Henrik, MacKay, Clare, Lovestone, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612013/ https://www.ncbi.nlm.nih.gov/pubmed/28800330 http://dx.doi.org/10.3233/JAD-170129

Ejemplares similares

Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
por: Firouzian, Azadeh, et al.
Publicado: (2018)

Aβ(42)/Aβ(40) and Aβ(42)/Aβ(38) Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer’s Disease: A Pilot Study
por: Koychev, Ivan, et al.
Publicado: (2018)

Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics
por: Kocagoncu, Ece, et al.
Publicado: (2020)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Neurons derived from individual early Alzheimer’s disease patients reflect their clinical vulnerability
por: Ng, Bryan, et al.
Publicado: (2022)

Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer’s disease
por: Koychev, Ivan, et al.
Publicado: (2019)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Preoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium
por: Xie, Zhongcong, et al.
Publicado: (2014)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
por: Startin, Carla M., et al.
Publicado: (2019)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid
por: Voyle, Nicola, et al.
Publicado: (2016)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy
por: Banerjee, Gargi, et al.
Publicado: (2020)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment
por: Garrett, Stephanie L., et al.
Publicado: (2019)

Mobility and associations with levels of cerebrospinal fluid amyloid β and tau in a memory clinic cohort
por: Tangen, Gro Gujord, et al.
Publicado: (2023)

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency
por: Rahhal, Samar, et al.
Publicado: (2023)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Relationship between amyloid and tau levels and its impact on tau spreading
por: Doré, Vincent, et al.
Publicado: (2021)

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
por: Selnes, Per, et al.
Publicado: (2010)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
por: Maxwell, Taylor J., et al.
Publicado: (2018)

Changes in Cerebrospinal Fluid Tau and β-Amyloid Levels in Diabetic and Prediabetic Patients: A Meta-Analysis
por: Lu, Yanhui, et al.
Publicado: (2018)

A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias
por: Said, Harun Muayad, et al.
Publicado: (2022)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K, et al.
Publicado: (2017)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis
por: Banerjee, Gargi, et al.
Publicado: (2021)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations
por: Brown, Jessica, et al.
Publicado: (2023)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
por: Delmotte, Koen, et al.
Publicado: (2021)

A comparison between tau and amyloid-β cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease
por: Turk, Katherine W., et al.
Publicado: (2022)

β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns
por: Jiang, Chenyang, et al.
Publicado: (2022)

Neuronal Network Excitability in Alzheimer’s Disease: The Puzzle of Similar versus Divergent Roles of Amyloid β and Tau
por: Kazim, Syed Faraz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0kjf210397hcssd91d1db8l1df